MX2012004295A - Composicion para el tratamiento de esclerosis multiple. - Google Patents
Composicion para el tratamiento de esclerosis multiple.Info
- Publication number
- MX2012004295A MX2012004295A MX2012004295A MX2012004295A MX2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple sclerosis
- mbp
- oligopeptides
- progression
- binding
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 3
- 102000015636 Oligopeptides Human genes 0.000 abstract 3
- 108010038807 Oligopeptides Proteins 0.000 abstract 3
- 102000047918 Myelin Basic Human genes 0.000 abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000054064 human MBP Human genes 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Los nuevos oligopéptidos, combinaciones de estos y proteínas de fusión compuestos por los oligopéptidos antes descritos son revelados. Los oligopéptidos son homólogos en las secuencias de aminoácidos a las partes seleccionadas de la secuencia de aminoácidos en la proteína básica de mielina (MBP) humana y son capaces de aliviar la progresión de la esclerosis múltiple por medio de la unió e inactividad de los anti auto anticuerpos de epitopo especifico de MBP (ESAMPCAA) involucrados en la unión y degradación catalítica de la MBP en el curso de la progresión de la Esclerosis Múltiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2009/000533 WO2011046462A1 (en) | 2009-10-12 | 2009-10-12 | Composition for treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012004295A true MX2012004295A (es) | 2012-08-15 |
Family
ID=42651912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012004295A MX2012004295A (es) | 2009-10-12 | 2009-10-12 | Composicion para el tratamiento de esclerosis multiple. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9896491B2 (es) |
EP (1) | EP2488196B1 (es) |
JP (1) | JP5709876B2 (es) |
KR (1) | KR20120103591A (es) |
CN (1) | CN102781465A (es) |
AU (1) | AU2009354040A1 (es) |
CA (1) | CA2780961C (es) |
DK (1) | DK2488196T3 (es) |
EA (1) | EA024832B1 (es) |
ES (1) | ES2566230T3 (es) |
MX (1) | MX2012004295A (es) |
WO (1) | WO2011046462A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2448685C2 (ru) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза |
EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
AU2013246870B2 (en) * | 2012-04-11 | 2016-06-23 | Lipoxen Technologies Limited | Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis |
WO2014152831A2 (en) * | 2013-03-14 | 2014-09-25 | Health Research, Inc. | Targeting peptides and uses thereof |
WO2015023132A1 (ko) * | 2013-08-14 | 2015-02-19 | 주식회사 카엘젬백스 | 다발성 경화증 치료 및 예방용 조성물 |
CN105541992A (zh) * | 2015-11-04 | 2016-05-04 | 武汉云克隆诊断试剂研究所有限公司 | 人MBP18.5kD变体抗原表位肽及特异性检测试剂盒 |
CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858980A (en) | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
IL115766A0 (en) | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
CA2494338C (en) | 1997-04-04 | 2007-07-17 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
CN102764425B (zh) | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
WO2008151847A1 (en) * | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Autoantibody binding peptides and their use for the treatment of vascular diseases |
EP2197906A1 (en) * | 2007-10-11 | 2010-06-23 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Fusion polypeptide comprising s-antigen repeat units |
WO2009056833A2 (en) * | 2007-10-31 | 2009-05-07 | Apitope Technology (Bristol) Limited | Composition |
-
2009
- 2009-10-12 WO PCT/RU2009/000533 patent/WO2011046462A1/en active Application Filing
- 2009-10-12 KR KR1020127012357A patent/KR20120103591A/ko not_active Application Discontinuation
- 2009-10-12 CA CA2780961A patent/CA2780961C/en active Active
- 2009-10-12 AU AU2009354040A patent/AU2009354040A1/en not_active Abandoned
- 2009-10-12 DK DK09827022.6T patent/DK2488196T3/en active
- 2009-10-12 MX MX2012004295A patent/MX2012004295A/es not_active Application Discontinuation
- 2009-10-12 JP JP2012534139A patent/JP5709876B2/ja not_active Expired - Fee Related
- 2009-10-12 ES ES09827022.6T patent/ES2566230T3/es active Active
- 2009-10-12 EA EA201290185A patent/EA024832B1/ru not_active IP Right Cessation
- 2009-10-12 EP EP09827022.6A patent/EP2488196B1/en active Active
- 2009-10-12 CN CN200980162867.4A patent/CN102781465A/zh active Pending
-
2012
- 2012-04-11 US US13/443,981 patent/US9896491B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5709876B2 (ja) | 2015-04-30 |
JP2013507437A (ja) | 2013-03-04 |
US9896491B2 (en) | 2018-02-20 |
CN102781465A (zh) | 2012-11-14 |
EP2488196B1 (en) | 2015-12-16 |
CA2780961A1 (en) | 2011-04-21 |
KR20120103591A (ko) | 2012-09-19 |
ES2566230T3 (es) | 2016-04-11 |
EA201290185A1 (ru) | 2012-11-30 |
CA2780961C (en) | 2018-10-02 |
WO2011046462A1 (en) | 2011-04-21 |
EP2488196A1 (en) | 2012-08-22 |
AU2009354040A1 (en) | 2012-05-31 |
EA024832B1 (ru) | 2016-10-31 |
US20120207820A1 (en) | 2012-08-16 |
DK2488196T3 (en) | 2016-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012004295A (es) | Composicion para el tratamiento de esclerosis multiple. | |
IN2014CN00414A (es) | ||
MY156286A (en) | Human il-23 antigen binding proteins | |
WO2009147248A3 (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
EA201270775A1 (ru) | Связывающие сывороточный альбумин молекулы | |
WO2012088461A3 (en) | Linker peptides and polypeptides comprising same | |
IL223989B (en) | Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto | |
RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
MX2014000054A (es) | Moleculas de union anti-alfa sinucleina. | |
MX348071B (es) | Variantes de fc. | |
UA104663C2 (en) | Antibody binding to cd127 | |
WO2009142460A3 (en) | Antibody-peptide fused synergibody | |
MY160552A (en) | Low protein infant formula with increased essential amino acids | |
IL225538A0 (en) | Methods for the identification of anti-immune reaction peptides of anti-citrullinates | |
WO2010136311A3 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
EP2805973A3 (en) | Humanised antibodies to Toll-like receptor 2 and uses thereof | |
WO2012083078A3 (en) | Croos-linked peptides and proteins, methods of making same, and uses thereof | |
WO2012083302A3 (en) | Compositions and methods for the treatment or prevention of human adenovirus-36 infection | |
WO2010136483A3 (en) | Antigen-binding proteins | |
WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |